The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCandless, E. E.
Right arrow Articles by Klein, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCandless, E. E.
Right arrow Articles by Klein, R. S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2006, 177: 8053-8064.
Copyright © 2006 by The American Association of Immunologists, Inc.

CXCL12 Limits Inflammation by Localizing Mononuclear Infiltrates to the Perivascular Space during Experimental Autoimmune Encephalomyelitis1

Erin E. McCandless2,{dagger}, Qiuling Wang2,*, B. Mark Woerner{ddagger}, James M. Harper*,§ and Robyn S. Klein3,*,{dagger},§

* Division of Infectious Diseases, {dagger} Department of Pathology and Immunology, {ddagger} Division of Pediatric Oncology, and § Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The inflammatory response in the CNS begins with the movement of leukocytes across the blood-brain barrier in a multistep process that requires cells to pass through a perivascular space before entering the parenchyma. The molecular mechanisms that orchestrate this movement are not known. The chemokine CXCL12 is highly expressed throughout the CNS by microendothelial cells under normal conditions, suggesting it might play a role maintaining the blood-brain barrier. We tested this hypothesis in the setting of experimental autoimmune encephalomyelitis (EAE) by using AMD3100, a specific antagonist of the CXCL12 receptor CXCR4. We demonstrate that the loss of CXCR4 activation enhances the migration of infiltrating leukocytes into the CNS parenchyma. CXCL12 is expressed at the basolateral surface of CNS endothelial cells in normal spinal cord and at the onset of EAE. This polarity is lost in vessels associated with an extensive parenchymal invasion of mononuclear cells during the peak of disease. Inhibition of CXCR4 activation during the induction of EAE leads to loss of the typical intense perivascular cuffs, which are replaced with widespread white matter infiltration of mononuclear cells, worsening the clinical severity of the disease and increasing inflammation. Taken together, these data suggest a novel anti-inflammatory role for CXCL12 during EAE in that it functions to localize CXCR4-expressing mononuclear cells to the perivascular space, thereby limiting the parenchymal infiltration of autoreactive effector cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The CNS is considered an immunologically specialized site where leukocyte trafficking is restricted by the blood-brain barrier (BBB),4 a complex organization of endothelial cells with tight junctions whose basement membranes are enveloped by glial foot processes (1, 2). Leukocytes that traverse the microvasculature must exit the perivascular space through this glial limitans to gain entry into the CNS parenchyma (3). In the autoimmune disease multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), the development of demyelinating lesions within the CNS is associated with the perivascular accumulation of mononuclear cells (4, 5). Studies suggest that myelin-specific T cells within these infiltrates enter the CNS parenchyma where they initiate inflammation, leading to the subsequent recruitment of effector cells such as macrophages and the activation of microglia (6, 7, 8). These effects ultimately result in demyelination and axonal damage, which produce the clinical deficits observed in MS and EAE. Although several adhesion molecules have been implicated in the interactions between mononuclear cells and the CNS endothelium (9, 10, 11), the chemoattractant molecules responsible for the movement of leukocytes into and out of the perivascular space are unknown. Knowledge of the chemoattractant molecules is of considerable interest for the development of therapies that would limit the development of inflammatory infiltrates in patients with MS.

It is well established that chemokines are essential for directing the movement of leukocytes into tissues (12). Chemokines are a superfamily of >50 structurally homologous chemotactic secreted proteins with their target cell specificity conferred by Gi-coupled, seven-transmembrane glycoprotein chemokine receptors. These proteins may be functionally classified into inflammatory and homeostatic members that direct leukocytes into parenchymal tissues during inflammation and into lymphoid tissues during immune surveillance, respectively (13, 14). Studies in rodents have suggested prominent roles for CCL2 and its receptor, CCR2, in the recruitment of monocytes and for CXCL9–11 and their receptor, CXCR3, in the immune responses of lymphocytes during the induction of EAE (15, 16, 17, 18, 19, 20). Although these and other studies have focused on inflammatory chemokines, the normal CNS has been shown to express several secondary lymphoid T lymphocyte chemoattractants including CCL19, CCL21, and CXCL12 (21, 22, 23). CCL19 and CCL21 promote dendritic and T cell interactions within lymphoid tissues, whereas CXCL12 regulates germinal cell polarity (24, 25). All three of these chemokines are expressed during EAE and can be detected in the cerebrospinal fluid of patients with both inflammatory and noninflammatory neurological diseases (26, 27). Recently, CXCL12 expression by endothelial cells and astrocytes in both active and inactive MS lesions was reported (28). The investigators speculated that endothelial CXCL12 might play a role in the extravasation of leukocytes during the development of inflammatory lesions in patients with MS.

The chemokine CXCL12 and its receptor, CXCR4, have well known roles in the patterning and function of the immune and nervous systems, where they localize various cell types to specific microenvironments (29). CXCL12 was originally identified as a bone marrow stromal cell-derived chemoattractant and proliferative factor for B cell precursors (30, 31). More recently, studies have demonstrated roles for CXCL12 and CXCR4 in multiple aspects of B and T cell development and in effector immune responses (32, 33, 34). CXCL12 is constitutively expressed by a variety of parenchymal tissues, including the CNS where it participates in neuronal proliferation, migration, axonal pathfinding, and myelination during development (35, 36, 37, 38). Although CXCL12 expression on neurons, microvasculature, and glial cells has been described, its role in the functioning of the normal or inflamed adult nervous system has not been extensively investigated. At many tissue sites, CXCL12 expression increases during autoimmune disease, and CXCR4 participates in the localization, proliferation, and activation of effector leukocytes at inflamed tissues sites (39, 40, 41). AMD3100, a bicyclam antagonist of CXCR4 signaling (42, 43), has been used to analyze the role of this receptor in a variety of biological processes as the targeted deletion of either CXCL12 or CXCR4 leads to embryonic lethality due to defects in the development of multiple organ systems (38, 44). Amelioration of disease in a variety of murine models of autoimmunity has been accomplished via chronic treatment with AMD3100 (45, 46), suggesting that CXCR4 activation is required during the expression of certain autoimmune diseases.

Because of the specialized functions of the CNS microvasculature and the high level and wide cellular range of expression of this chemokine in the normal, relatively immunologically quiescent CNS, we thought it unlikely that CXCL12 would function to promote extensive leukocyte trafficking into the normal CNS parenchyma. The endothelial cell expression of CXCL12 in the CNS, where there is little immune surveillance and no intraparenchymal lymphoid tissues, is curious and suggests that this chemokine could act to regulate leukocyte extravasation under normal and inflammatory circumstances. In this study we report that CXCL12 is expressed by normal spinal cord white matter endothelium at the basolateral surface. During induction of EAE, CXCL12 expressed is increased and is associated with perivascular mononuclear cell infiltrates expressing CXCR4. Inhibition of CXCR4 via administration of AMD3100 results in extensive migration of mononuclear cells out of the perivascular space and into the parenchyma, leading to increased inflammatory mediators and worsened clinical disease. Together, these studies suggest that CXCL12 plays a role in limiting the intraparenchymal migration of mononuclear cells during CNS autoimmune disease, identifying a novel anti-inflammatory role for this chemokine within the CNS.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animals and Abs

C57BL/6 mice (The Jackson Laboratory) were maintained in pathogen-free conditions (Department of Comparative Medicine, Washington University, St. Louis, MO). Abs used include the following: CXCL12 rabbit polyclonal Ab (PeproTech); actin Abs (Sigma-Aldrich); IgG isotype control Abs (Jackson ImmunoResearch Laboratories); CXCR4 polyclonal Abs (Leinco Technologies); monoclonal rat anti-mouse-CD31 (PECAM), CD11b, mouse anti-human CD3, and rat anti-mouse-CD45 (BD Pharmingen); rat anti-mouse glial fibrillary acidic protein (GFAP) Ab (Zymed Laboratories); monoclonal anti-NeuN Ab (Chemicon International);and fluorescently conjugated Abs against CD3, CD4, CD8, CD19, CD11b, CD45, and Gr-1 (BD Pharmingen).

EAE induction

Active EAE was induced in 8- to 12-wk-old female C57BL/6 (The Jackson Laboratory) mice by s.c. immunization with a murine myelin oligodendroglial glycoprotein (MOG) peptide (MOGp35-55) (Sigma Genosys) in PBS emulsified 1:1 with IFA supplemented with 500 µg/ml inactivated Mycobacterium tuberculosis for a total 50-µg immunizing dose of MOGp35-55. Mice received 300 ng of pertussis toxin (List Laboratories) i.v. at the time of immunization and 48 h later, as previously described (18). For adoptive transfer experiments, MOG-specific T cells were generated as previously described (47). Activated cells were collected and transferred retro-orbitally at 2.5 x 106 cells per mouse. Mice from all experiments were graded for clinical manifestations of EAE by the following criteria: 1, tail weakness; 2, difficulty righting; 3, hind limb paralysis; 4, forelimb weakness or paralysis; 5, moribund or dead.

In vivo AMD3100 treatment

Subcutaneous osmotic pumps (Alzet) loaded with 2 or 20 mg/ml AMD3100 in sterile PBS or PBS alone were used according to the manufacturer’s instructions. The infusion rate was 0.25 µl/h and consistent administration was achieved for 14 days postimplantation of the pumps. Osmotic pumps were implanted on days 0 and 9 postimmunization with MOGp35-55 or on day 0 after adoptive transfer of MOG-specific Th1 cells. For hemopoietic stem cell mobilization experiments, animals were injected with 5 mg/kg AMD3100 s.c. 1 h before sacrifice via exsanguination.

CNS histology and myelin staining

Animals were deeply anesthetized with a xylazine/ketamine mixture and perfused intracardially with normal saline and then with 4% paraformaldehyde on days 0, 10, and 14 postimmunization. Spinal cords were collected embedded in paraffin or frozen medium, and both transverse and longitudinal sections were generated and stained with H&E. For myelin evaluation, frozen sections were stained with FluoroMyelin Green fluorescent stain according to the manufacturer’s instructions (Molecular Probes).

Quantitative analysis of lesion size

Fixed, H&E-stained transverse and longitudinal sections of spinal cords from either PBS-treated (n = 3) or AMD3100-treated (n = 3) mice with an EAE grade of 2 were analyzed by a blinded observer under light microscopy. Measurements of white matter lesions were made to the nearest 5 µm via an intra-eyepiece reticle representing 1 mm at x100 total magnification, with subdivisions representing 10 µm. Inflammatory cell identification was confirmed by morphology at x400 total magnification. Because the vast majority of lesions approximated triangular shapes, area was calculated by multiplying the maximum measurement in each dimension and dividing by two. Mean lesion size for the respective treatment groups was calculated by summation of all areas calculated and division by the total number of lesions measured in each group (nPBS = 91; nAMD3100 = 156).

Flow cytometry

Cells were isolated from the spinal cords of mice with EAE as previously described (18) and stained with fluorescently conjugated Abs to CD3, CD4, CD8, CD19, CD11b, CD45, and Gr-1 (see above). Data collection and analysis were conducted using a FACScalibur flow cytometer using CellQuest software (BD Biosciences). For fluorescence analysis, a bivariate dot plot of forward vs side scatter was generated and separate regions for lymphocytes and monocytes were delineated. Fluorescent analysis displays then were generated by gating on either lymphocytes or monocytes/ macrophages.

Quantitative RT-PCR (QPCR)

Total RNA was prepared and QPCR was performed as previously described (48) using primers for IL-2, TNF-{alpha}, IFN-{gamma}, IL-10, chemokines, and chemokine receptors whose sequences have been previously published (18, 48). Calculated copies were normalized against copies of the housekeeping gene GAPDH.

Immunohistochemistry

Paraffin sections underwent deparaffinization, Ag recovery, and permeabilization as previously described (48, 49), and frozen sections were permeabilized, blocked, and stained as previously described (48). For detection of CXCL12 and anti-CD31 (PECAM) or anti-NeuN (neuronal marker), Image-iT FX signal enhancer (Molecular Probes) solution was used according to the manufacturer’s instructions. Primary Abs (see above) were used at the following dilutions: anti-CXCL12 (1/20), anti-mPECAM-1 (1 µg/ml), monoclonal anti-NeuN (1/50), CXCR4 (1 µg/ml), and GFAP, CD11b CD3, or CD45 (1–10 µg/ml). Primary Abs were detected with secondary goat anti-rabbit or mouse IgG conjugated to Alexa Fluor 594 or Alexa Fluor 488 (Molecular Probes) for immunofluorescence staining, and nuclei were counterstained with 4',6'-diamidino-3-phenylindole (DAPI) or ToPro3. Control sections were incubated with antisera in the presence of a 100 µmol/L excess of peptide or with isotype-matched IgG. Sections were analyzed using a Zeiss LSM 510 laser-scanning confocal microscope and accompanying software (Zeiss). Volocity image analysis software (Improvision) was used to generate and analyze three-dimensional renderings of confocal images. Stained regions were identified by applying a classifier to exclude objects smaller than 0.1 µm3 and pixels of intensity of <45 (scale 0–225).

Adoptive transfer of AMD3100 mobilized stem cells

Female C57BL/6 mice were immunized with MOGp35-55, and pertussis toxin was administered on days 0 and 2 postimmunization as described above. On day 10 postimmunization, AMD3100 (5 mg/kg) was administered to a group of naive female C57BL/6 mice. One hour later, blood was harvested into heparin-containing syringes and PBMC were prepared using Lympholyte-M (Cedarlane Laboratories). Hemopoietic precursor cells (HPCs) were isolated by negative selection by incubating the PBMCs with Mouse Lineage Mixture (Caltag Laboratories), an anti-cell marker Ab mixture, followed by incubation with anti-biotin microbeads (Miltenyi Biotec), and purified hemopoietic stem cells were obtained via magnetic columns (Miltenyi Biotec). At day 10 postimmunization, MOG-immunized mice received 280,000 stem cells in HBSS with 1% FCS and 20 mM HEPES (vehicle) or vehicle alone i.v., which corresponded to the total number of hemopoietic stem cells recovered from one AMD3100-treated animal. Mice were followed on a daily basis and scored for clinical EAE as described above. In some experiments, CD45.1 HPCs were isolated from the peripheral blood of AMD3100-treated mice and i.v. transferred to MOG-immunized CD45.2 mice at day 10 postimmunization, and blood from recipient mice was examined for the presence of transferred CD45.1 cells via flow cytometry at day 14 postimmunization.

Statistical analyses

All values are expressed as mean ± SEM. The Student t test was used to determine the statistical significance of QPCR, histological, and flow cytometry analyses, whereas mean maximal disease severity significance was determined by the Mann-Whitney nonparametric test with values of p < 0.05 considered statistically significant for all analyses. For analysis of disease severity curves, statistical significance of curves was determined using the Wilcoxon sign rank test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Spinal cord CXCL12 expression localizes to the basolateral surface of microendothelial cells

To define the roles of CXCL12 and CXCR4 in autoimmune disease of the spinal cord, we used the active immunization model of EAE induced by administration of the MOGp35-55 peptide. Expressions of CXCL12 and its receptor, CXCR4, have not been evaluated extensively in the normal or diseased spinal cord. Examination of CXCL12 mRNA expression via QPCR of the spinal cord from unimmunized mice and at 9 (clinical score 0) and 14 days (clinical score 2) postimmunization with MOGp35-55 revealed high levels of expression in the normal tissue that are significantly increased at the peak of clinical disease (Fig. 1A). Similar evaluation of other secondary lymphoid chemokines, CCL19 and CCL21, revealed that CCL19, but not CCL21, increased during induction of EAE (Fig. 1A). Previous studies of CCL19 and CCL21 in the brains of mice with adoptive transfer EAE detected increased expression of both of these chemokines (21, 26). The absence of CCL21 up-regulation in the spinal cord of animals with active immunization EAE suggests a differential role for CCL21 in various CNS compartments.


Figure 1
View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 1. Expression of CXCL12 in normal and inflamed spinal cord. A, C57BL/6 mice were evaluated for expressions of CCL19, CCL21 and CXCL12 mRNAs at 0, 9, and 14 days postimmunization with MOGp35-55 via QPCR. Chemokine data are expressed as average copies per copy of GAPDH for groups of 3–5 mice in three separate experiments and presented as ± SEM. (*, p < 0.05). B, Endothelial localization (PECAM and Alexa Fluor 488; green) of CXCL12 (Alexa Fluor 555; red) in spinal cord sections from nonimmunized (left upper panel) and immunized mice at (left lower panel) 10 days postimmunization with MOGp35-55. Inset, Colocalization of CXCL12 (Alexa Fluor 555; red) within motor neurons (NeuN; Alexa Fluor 488, green) of the gray matter. Quantification of fluorescence intensity during confocal microscopy for CXCL12 (red stain and line) and PECAM (green stain and line) are shown next to microphotographs. Double-headed arrows indicate area transected in line plot depictions. Nuclei are counterstained with ToPro3 (blue); scale bars = 10 µm. C, Colocalization of PECAM (Alexa Fluor 488, green) and CXCL12 (Alexa Fluor 555, red) in spinal cord sections at 14 days postimmunization with MOGp35-55 demonstrates heterogeneity in CXCL12 polarity with inflamed microvessels displaying complete colocalization with PECAM (left upper panel, arrowheads) and inflammation-associated disruption of CXCL12 polarity (right upper panel). Arrows indicate PECAM+ vessels without inflammatory infiltrates (left upper panel). Quantification of fluorescence intensity during confocal microscopy for CXCL12 (red stain and line) and PECAM (green stain and line) are shown (lower panel). Double-headed arrows indicate area transected in line plot depictions. Nuclei are counterstained with ToPro3 (blue); scale bars = 100 µm (left panel) and 10 µm (right panel). D, Three-dimensional reconstructions of double-labeled microvessels in spinal cord sections of nonimmunized (left panel) and MOG-immunized (right panel) mice at 14 days postimmunization with CXCL12 (red) and PECAM (green). These images have been intentionally rotated to enhance the ability to see the staining in three dimensions.

 
The up-regulation of spinal cord CXCL12 expression during the induction of EAE suggested that this chemokine might be important in leukocyte migration during CNS inflammation. Prior studies of CXCL12 mRNA expression in brain had localized CXCL12 to subpopulations of forebrain neurons and to the microvasculature of both gray and white matter (23). To better evaluate endothelial cell expression of CXCL12 within the spinal cord, double-labeled immunofluorescent confocal microscopy was performed on spinal cord sections from normal mice and from those derived 10 and 14 days postimmunization with the MOGp35-55 peptide. In both normal and inflamed spinal cords, the CXCL12 protein colocalized with the endothelial cell marker PECAM-1 within both gray (not shown) and white matter (Fig. 1B). Subpopulations of neurons within the gray matter also expressed CXCL12, as demonstrated by double labeling with the neuronal nucleus marker NeuN (Fig. 1B, upper left panel, inset). In spinal cord sections derived from normal mice and from those obtained 10 days postimmunization with MOGp35-55, quantification of fluorescence intensity during confocal microscopy revealed a polarity in peak endothelial cell CXCL12 expression that localized this chemokine to the basolateral surface of microendothelial cells (parenchymal side), opposing the perivascular space (Fig. 1B, right panels). Although PECAM staining could be detected easily in vessels of noninflamed spinal cord, the staining intensity was decreased at day 10 postimmunization with MOGp35-55, a time point at which mononuclear cells have begun to enter the CNS in search of Ag. Interestingly, analyses of spinal cord sections obtained from animals at day 14 postimmunization, which is at the peak of disease, revealed that vessels surrounded by numerous mononuclear cells entering the parenchyma have more diffuse PECAM staining and complete loss of CXCL12 polarity (Fig. 1C, compare top left and right panels). Quantitative confocal microscopy of these highly inflamed vessels demonstrates a more even distribution of CXCL12 and PECAM, with loss of the previous basolateral peak in CXCL12 expression (Fig. 1C, bottom panel). Prior studies have indicated that activation of CNS microvasculature is associated with more diffuse distribution of PECAM staining (50). Three-dimensional reconstructions of vessels stained with CXCL12 (red) and PECAM (green) better demonstrated this reversal of the detection of expression with noninflamed and day 10 vessels exhibiting red exteriors and green interiors and severely inflamed day 14 vessels exhibiting green exteriors and red interiors (Fig. 1C). Experiments using control IgG Abs did not demonstrate any specific staining (data not shown). These results suggest that CXCL12 exerts its chemoattraction toward the parenchymal side of vessels and that this polarity of expression is disrupted during endothelial cell activation and increased BBB permeability.

CXCR4 is expressed by both infiltrating mononuclear cells and parenchymal glia

QPCR evaluation of the chemokine receptors for CCL19 and CXCL12, CCR7 and CXCR4, respectively, similarly revealed significantly increased expression of these chemokine receptor mRNAs at the peak of clinical disease, with CXCR4 exhibiting the highest fold increase (Fig. 2A). Identification of cells expressing CXCR4 via double-labeled immunofluorescent microscopy with anti-CXCR4 Abs revealed them to be CD11b-, GFAP-, and CD45-expressing macrophages/microglia, astrocytes, and leukocytes, respectively (Fig. 2B). Interestingly, many of the CD11b+ and CD45+ cells that expressed CXCR4 were vessel associated. The pattern of expression of CXCR4 was quite distinct from GFAP, with CXCR4 more centrally located and GFAP characteristically within astrocyte processes (Fig. 2B). The use of isotype control Abs did not result in any specific staining (Fig. 2B). CXCR4 expression was limited to scattered cells within the white matter of spinal cord tissues from unimmunized animals (Fig. 2B). The location and morphology of these cells suggest that they are oligodendrocytes. Taken together, these results indicate that the increased levels of CXCR4 expression observed during the induction of EAE are the results of both infiltrating CXCR4-expressing mononuclear cells and the expression of CXCR4 by activated astrocytes and microglia within the parenchyma.


Figure 2
View larger version (75K):
[in this window]
[in a new window]
  		FIGURE 2. Expression of CXCR4 during induction of EAE. A, C57BL/6 mice were evaluated for expressions of CCR7 and CXCR4 mRNAs at 0, 9, and 14 days postimmunization with MOGp35-55 via QPCR. Chemokine data are expressed as average copies per copy of GAPDH for groups of 3–5 mice in three separate experiments and presented as ± SEM. (*, p < 0.05). B, Cellular localization of CXCR4 in spinal cord sections from unimmunized mice and from those with EAE at 14 days postimmunization with MOGp35-55. Representative sections are displayed with immunohistochemical analyses for CXCR4 (red) expression within the white matter of spinal cord sections from unimmunized (UI) mice (left upper panel) and double labeling for CD45 (right upper panel, green), CD11b (left lower panel, green), and GFAP (right lower panel, green) expressing cells within sections from immunized mice. Nuclei are counterstained with DAPI. Left upper panel inset: staining with isotype control IgG Abs. Arrowheads indicate CXCR4-expressing glia in unimmunized spinal cord sections and colocalization of CXCR4 within vessel associated CD45+ and CD11b+ macrophages (right upper and left lower panels) and GFAP+ astrocytes (right lower panel). Scale bars = 10 µm except for CXCR4/GFAP photomicrograph, which is higher power magnification with scale bar = 20 µm; analyses were performed on sections from four MOG-immunized animals.

 
Loss of CXCR4 activation leads to increased clinical severity of EAE

Based on the expression patterns of CXCL12 and CXCR4 in the spinal cord microvascular endothelium and perivascular/parenchymal mononuclear cells, we hypothesized that these proteins might play a role in the movement of leukocytes out of the perivascular space during the development of autoimmune inflammation. To test this hypothesis, we administered AMD3100 to animals during the induction of active immunization EAE. AMD3100 is a bicyclam competitive antagonist of CXCL12 binding to CXCR4 (43). This compound has been widely used in basic and clinical studies for evaluating CXCR4 function. AMD3100 induced a dose-dependent, significant worsening of clinical severity when administered to animals during the first 2 wk of the disease (Fig. 3A). Disease severity in AMD3100-treated animals with EAE displayed a plateau phase without significant recovery, whereas the disease curves of PBS-treated animals were more typical of monophasic EAE induced by immunization with the MOGp35-55 peptide (Fig. 3, A and B). The higher dose of AMD3100 (4 mg/kg/day) has been used to inhibit CXCR4 activation in multiple animal models (45, 46, 51). Thus, this dose was used for the remainder of our experiments. Because CXCL12 is highly expressed in secondary lymphoid tissues and it was possible that AMD3100 affected immunization, we also treated cohorts of animals with AMD3100 beginning at day 9 postimmunization, a time point at which we and others have previously demonstrated that autoreactive T cells are present and have begun trafficking into the CNS (18, 53). Treatment with AMD3100 beginning at day 9 postimmunization also led to significant worsening of disease (Fig. 3B), suggesting that the development of inflammation at the spinal cord was the target of AMD3100. Finally, administration of AMD3100 to mice during adoptive transfer of MOG-specific T cells also led to significantly worsened disease but with more pronounced recovery (Fig. 3C), suggesting that CXCR4 antagonism does not lead to worsened EAE via effects at peripheral lymphoid tissues but rather that this worsening is due to direct effects at the spinal cord. Importantly, in all experiments AMD3100 led to a significant increase in overall clinical severity of EAE and a trend toward increased overall incidence but did not appreciably alter the time of onset of disease (Fig. 3 and Table I). In addition, the mean maximal disease scores were significantly higher only in those animals treated with the standard dose of AMD3100 (4 mg/kg/day) (Table I). Thus, CXCR4 is unlikely to play a role in the initiation of disease by MOGp35-55-specific T cells but does play a role in the progression of inflammation.


Figure 3
View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 3. CXCR4 antagonism increases the clinical severity of EAE. A, C57BL/6 mice immunized with 50 µg of MOGp35-55 were treated with PBS ({blacksquare}) (n = 21), AMD3100 (AMD) at 0.4 mg/kg/day ({triangleup}) (n = 13), or 4.0 mg/kg/day ({diamond}) (n = 17) on days 0–14 postimmunization. B, Similarly immunized C57BL/6 mice were treated with PBS ({blacksquare}) (n = 18) or AMD3100 at 4.0 mg/kg/day ({diamond}) (n = 16) on days 9–23 postimmunization. C, Adoptive transfer of MOGp35-55-specific Th1 cells into C57BL/6 mice treated with PBS ({square}) (n = 6) or AMD3100 at 4.0 mg/kg/day ({diamond}) (n = 6) on days 0–14 posttransfer. Clinical signs of disease were monitored daily and graded on a scale of 0–5 as described previously. Results are expressed as mean disease scores ± SEM, and curves were analyzed using the Wilcoxon sign rank test (**, p < 0.001; *, p < 0.05). Gray bars indicate timing and lengths of treatment periods.

 

View this table:
[in this window]
[in a new window]
  		Table I. Effect of AMD3100 on EAE clinical disease parameters

 
Loss of CXCR4 activation leads to widening of perivascular infiltrates

To examine the basis of our clinical findings, we analyzed spinal cord tissues from MOGp35-55-immunized animals treated with PBS vs AMD3100. Histological examination of spinal cord sections from PBS and AMD3100-treated animals with EAE of the same clinical grade revealed startling differences in the extent of the inflammatory infiltrates within the ventral white matter at day 14 postimmunization (Fig. 4A). Although the PBS-treated animals developed the typically intense perivascular mononuclear cell infiltrates with moderate parenchymal infiltration, AMD3100-treated animals developed extensive mononuclear parenchymal inflammatory infiltration, essentially obliterating the ventral white matter region. Because AMD3100 mobilizes bone marrow stem cells and thus could theoretically alter the initial neutrophilic component during early EAE induction, we also performed histologic analyses of spinal cords from PBS- and AMD3100-treated animals at 9 and 10 days postimmunization, which did not reveal differences in the neutrophilic infiltrate (data not shown). An analysis of spinal cord sections from PBS- and AMD3100-treated mice with myelin stains at day 14 postimmunization revealed increased demyelination as a result of AMD3100 treatment (Fig. 4B). Quantitative analyses of lesions revealed a significant increase in the average areas of lesions in AMD3100-treated mice with EAE compared with those that received PBS (Fig. 4C). Taken together, these results are consistent with the hypothesis that CXCR4 plays a role in adjusting the severity of disease by limiting the extent of the parenchymal infiltration of mononuclear cells.


Figure 4
View larger version (65K):
[in this window]
[in a new window]
  		FIGURE 4. Histological analyses of spinal cord tissues from PBS- and AMD3100-treated mice with EAE induced by MOGp35-55 immunization. A, Transverse (top) and longitudinal (bottom) sections from PBS- and AMD3100-treated mice with grade 2 EAE. Perivascular lesions typical of acute EAE were observed in the spinal cords of PBS-treated mice (arrowheads), whereas spinal cords from AMD3100-treated mice with EAE contained large diffuse areas of infiltrating cells (arrow). Lesions in both groups of mice were comprised of mononuclear cells (top insets and longitudinal sections; arrows indicate vessels). Scale bars = 100 µm (transverse sections), 20 µm (insets), and 10 µm (longitudinal sections). (23 ). B, Transverse sections from PBS- (left; grade 3) and AMD3100-treated (right; grade 4) mice with EAE stained with FluoroMyelin Green fluorescent myelin stain. Nuclei are counterstained with DAPI. Scale bar = 50 mm. C, Quantification of CNS lesion numbers in PBS- (open bar) and AMD3100-treated (gray bar) mice immunized with grade 2 EAE. Error bars represent SEM; n = 4 mice per group. A two-tailed t test showed significant difference between the groups (*, p = 0.0048).

 
Expression of CXCL12 and CXCR4 are decreased in lymphoid tissue during the induction of EAE

Because CXCL12 plays an essential role in the localization of lymphocytes to specific zones within lymphoid tissues, we wondered whether its expression patterns were altered during the induction of CNS autoimmunity. QPCR analyses of CXCL12 and CXCR4 revealed that mRNAs for these molecules are significantly decreased during the induction of EAE (Figs. 5, A and B). For control purposes, expressions of CCL19, CCL21, and CCR7 mRNAs were also analyzed, with similar results. These data suggest that migration of mononuclear cells out of lymphoid tissues during the initiation of CNS autoimmune disease may be partly due to release from the localizing effects of secondary lymphoid chemokines via decreased expressions of both ligands and receptors. In addition, they support the notion that AMD3100 is unlikely to exacerbate EAE through effects at peripheral lymphoid tissues.


Figure 5
View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 5. Peripheral lymphoid tissue responses and bone marrow mobilization during EAE. A, C57BL/6 mice were evaluated for expression of CCL19, CCL21, CXCL12, CCR7, and CXCR4 mRNAs at 0, 9, and 14 days postimmunization with MOGp35-55 via QPCR. Chemokine data are expressed as average copies per copy of GAPDH for groups of 3–4 mice in two separate experiments and presented as ± SEM. (*, p < 0.05). B, Adoptive transfer of HPCs does not alter clinical severity of EAE. HPCs were isolated from the peripheral blood of AMD3100-treated mice and i.v. transferred to MOG-immunized mice at day 10 postimmunization. Control mice received vehicle alone i.v. Mice were followed and scored for the severity of clinical disease. Data are presented as average clinical disease scores ± SEM and are representative of two experiments, each with n = 6–10 animals per treatment group. C, PBMCs collected from recipient mice at day 14 postimmunization were stained for the presence of the transferred CD45.1 cells. Representative FACS plots are shown (left panel, isotype control; right panel, CD45.1)

 
AMD3100 has been shown to efficiently mobilize HPCs, which use CXCR4 for localization to proliferative microenvironments within the bone marrow (53, 54, 55). To determine whether AMD3100-mediated mobilization of HPCs affected the induction of EAE, we i.v. transferred AMD3100-mobilized HPCs from CD45.1 congenic mice into MOG-immunized C57BL/6 (CD45.2) mice at day 10 postimmunization, a time point when encephalitogenic T cells have begun trafficking into the CNS, and we observed animals for alterations in the clinical severity of the disease. As indicated in Fig. 5B, there was no difference in the clinical severity of EAE in animals that received vehicle vs those that received vehicle containing HPCs. Flow cytometric analysis of PBMCs obtained from recipient mice at day 14 postimmunization demonstrates that, although transferred HPCs did not affect disease course, they survived and began to express CD45 (Fig. 5C). Taken together, our data suggest a separate local effect of CXCR4 within the spinal cord during the induction of EAE.

CXCR4 inactivation leads to increased intraparenchymal migration of mononuclear cells

Our histological results demonstrated that AMD3100-treated mice with EAE did not develop the usual intense perivascular infiltrates but instead had widening of intraparenchymal lesions with increased demyelination of white matter tracts. To determine whether loss of CXCR4 activation affected the overall numbers of leukocytes trafficking into the spinal cord, we analyzed leukocyte infiltrates in PBS- and AMD3100-treated mice with EAE of similar clinical grades via flow cytometry (Fig. 6). Leukocytes were isolated from individual spinal cords from PBS- and AMD3100-treated mice with EAE at clinical grade 2 and examined for expression of CD3, CD4, CD8, CD19, CD45, CD11b, and Gr-1. Although the percentages of T and B lymphocytes and granulocytes were similar between the two treatment groups (data not shown), the percentage and total numbers of activated microglia (CD45highCD11blow) was significantly increased in the AMD3100-treated groups compared with those that had received PBS vehicle (Fig. 6, A and B). Consistent with this finding, we also observed a significant decrease in the numbers of resting microglia (CD45lowCD11blow) in AMD3100-treated animals. Examination of total cell numbers similarly did not reveal any large differences in the numbers of infiltrating leukocytes between the two treatment groups with EAE; however, a significant increase was observed in the penetration of CD45+ cells in the parenchyma of AMD3100-treated animals compared with those treated with PBS in all grades of EAE (Fig. 6C). CD45+ cells comprising focal perivascular infiltrates in the PBS-treated mice were instead dispersed throughout the white matter in the AMD3100-treated animals. The increased penetration of CD45+ cells in AMD3100-treated animals with the most severe disease (grade 4) was also associated with an increase in more dimly staining CD45+ cells, presumed to be microglia, when compared with PBS-treated mice with more severe disease (grade 3) (Fig. 6C, compare the two right panels). Similar dramatic differences in the positions of CD3- and CD11b-expressing cells were also observed between the two treatment groups (Fig. 6, D and E, respectively). Spinal cord sections from PBS-treated mice had focal perivascular areas containing intensely stained CD3-expressing T cells and CD11bhigh-expressing macrophages, whereas the CD3- and CD11b-expressing cells detected in the sections from AMD3100-treated mice were more dispersed and, in the case of CD11b-expressing cells, consisted of both CD11bhigh macrophages and CD11blow microglia (Fig. 6E, insets). The increased penetration of CD11b-expressing cells and the enhanced microglial activation in the AMD3100-treated animals were also associated with increased demyelination as assessed by double-labeled immunofluorescent labeling of myelin and CD11b expression in spinal cord sections from grade 3 PBS-treated and grade 4 AMD3100-treated mice (Fig. 6E). These data suggest that CXCR4 determines the extent of mononuclear cell parenchymal penetration and microglial activation during EAE.


Figure 6
View larger version (74K):
[in this window]
[in a new window]
  		FIGURE 6. CXCR4 antagonism during EAE leads to increased microglial activation. A and B, Cells were isolated from the spinal cords of PBS- and AMD3100-treated mice with grade 2 EAE and stained with fluorescently conjugated anti-CD3, anti-CD4, anti-CD8, antiCD19, anti-CD45, anti-CD11b, and anti-Gr-1 mAbs and analyzed by flow cytometry. A, Scatter plot analyses of CD45/CD11b-expressing cells from spinal cords of PBS- (left panel) and AMD3100-treated (right panel) mice with EAE obtained via gating of monocyte/macrophage using a bivariate dot plot of forward vs side scatter. Numbers in quadrants drawn within CD45+CD11b+ group represent percentages of total CD45+ and CD11b+ cells. B, Total numbers of immunophenotyped cells derived from spinal cords of PBS- (white bars) and AMD3100-treated (gray bars) mice with EAE. Average values of immunophenotyped cells are presented as total cell numbers from individual spinal cord samples from a representative of four experiments with 3–9 mice per treatment group ± SEM. (*, p < 0.05). C, Immunohistochemical analyses of CD45+ cells (green) within spinal cord sections of PBS- and AMD3100-treated mice with grade 2 EAE (left two panels) and grades 3 and 4 EAE (right two panels, respectively). Nuclei have been counterstained with DAPI. Scale bar = 50 µm. Inset in the far right panel depicts higher power view of CD45+ cells; arrowheads indicate CD45high macrophages and CD45low microglia. Scale bar = 20 µm. D, Immunohistochemical analyses of CD3+ cells (red) within spinal cord sections of PBS- (left panel) and AMD3100-treated (right panel) mice with EAE (PBS, grade 3; AMD3100, grade 4). Nuclei have been counterstained with DAPI. Scale bar = 20 µm. Data are representative of staining experiments performed on four mice. E, Immunohistochemical analyses of CD11b+ cells (red) and the extent of demyelination (green) within spinal cord sections of PBS- (left panel) and AMD3100-treated (right panel) mice with EAE (PBS, grade 3; AMD3100, grade 4). Nuclei have been counterstained with DAPI. Insets depict CD11b+ cells alone; arrowheads indicate CD11bhigh macrophages and CD11blow microglia. Scale bar = 20 µm. Data are representative of staining experiments performed on four mice.

 
Treatment with AMD3100 leads to increased inflammatory mediators during EAE

Because CXCR4 antagonism led to worsened clinical severity of EAE with a widening of inflammatory infiltrates and increased microglial activation and demyelination, we evaluated the mRNA expression of inflammatory mediators and chemokines within the spinal cords of PBS- and AMD3100-treated mice with grade 2 EAE. QPCR evaluation revealed that AMD3100-treated mice with EAE had significantly increased levels of Th1 cytokines IL-2, TNF-{alpha}, and IFN-{gamma}, whereas levels of IL-10 were lower than those in PBS-treated mice, consistent with an anti-inflammatory role for CXCL12/CXCR4 during EAE (Fig. 7A). Analysis of the regulatory T cell markers CD25, FoxP3, and TGF-beta (56) did not reveal any significant differences (data not shown). With the exception of CXCL10, levels of chemokine (Fig. 7B) and chemokine receptor (not shown) mRNAs previously observed to be increased in the spinal cord during EAE induction were similar in the two treatment groups. Because CXCL10 is expressed by activated glia and macrophages that infiltrate the CNS (57, 58), this finding is also consistent with our data suggesting that loss of CXCR4 activity leads to the increased trafficking of mononuclear cells with enhancement of the subsequent parenchymal inflammatory responses.


Figure 7
View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 7. CXCR4 antagonism increases Th1 inflammatory mediators within the spinal cord during EAE. PBS- (open bars) and AMD3100-treated (filled bars) C57BL/6 mice with grade 2 EAE were evaluated for expression of IL-2, IFN-{gamma}, TNF-{alpha}, and IL-10 (A) and CCL2, CCL3, CCL4, CCL5, CCL19, CCL21, CXCL9, CXCL10, and CXCL12 (B) mRNAs via QPCR. Representative data are expressed as average copies per copy of GAPDH for groups of 3–5 mice immunized with MOGp35-55 in one of three experiments and presented as ± SEM (*, p < 0.05).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the present study we demonstrate that the chemokine CXCL12 is expressed on the basolateral surface of spinal cord microvasculature, where it functions to prevent CXCR4-expressing mononuclear cells from migrating out of the perivascular space and into the parenchymal tissue during CNS autoimmune disease. This distribution pattern is altered during the onset of inflammation, suggesting that disruption of this chemokine gradient could play a role in the extravasation of leukocytes into the CNS parenchyma. Chronic administration of AMD3100, a small molecule inhibitor of CXCR4 signaling, during the induction of EAE led to extensive intraparenchymal migration of mononuclear cells with the resultant activation of microglia, extensive demyelination, increased inflammation, and worsened clinical disease. Normally, EAE and the disease it models, MS, are characterized by intense perivascular cuffs of mononuclear cells with the limited parenchymal migration of leukocytes associated with circumscribed demyelination. In our AMD3100-treated animals, these tight perivascular lesions were replaced by extensive sheets of mononuclear cells infiltrating the ventral white matter, with subsequent damage to the myelin sheaths. Although AMD3100-treated animals with EAE had worsened clinical disease, higher levels of spinal cord Th1 cytokines, and extensive demyelination, the total numbers of mononuclear cells were similar to their PBS-treated counterparts. Interestingly, significant differences were observed in the numbers of CD45highCD11blow cells (activated microglia) and CD45lowCD11blow cells (resting microglia), which were higher and lower, respectively, in the AMD3100-treated animals with EAE. These data suggest that AMD3100 treatment is associated with an increase in microglial activation and not increased recruitment of peripheral leukocytes. In support of this interpretation, we observed a dramatic difference in the intraparenchymal positions of these mononuclear cells, with cells located throughout the ventral white matter, suggesting that CXCR4 plays a role in preventing mononuclear cell trafficking out of the perivascular space and into the CNS parenchyma, thereby limiting the extent of inflammation within the parenchyma.

Although a variety of studies have analyzed the expression patterns of CXCL12 and CXCR4 in the developing and adult CNS, there has been little work describing a role for these molecules in the pathogenesis of CNS diseases. The detection of CXCL12 in the cerebrospinal fluid of patients without neuroinflammatory diseases indicates that this chemokine does not necessarily promote inflammation within the CNS (28). Indeed, our data would argue that CXCL12 prevents CXCR4-expressing mononuclear cells from penetrating the CNS parenchyma, where they would contribute to microglial activation and demyelination via the actions of inflammatory mediators such as IFN-{gamma} (59, 60). Consistent with this argument, Stumm et al. (23) previously reported that the administration of LPS is associated with decreased expression of CXCL12 by CNS endothelial cells, supporting the notion that CXCL12 does not promote activation of the CNS microvasculature. The observed redistribution of CXCL12 in activated microendothelial cells with perivascular infiltrates argues instead that directed expression of CXCL12 may be altered in response to this activation. Thus, CXCL12 detected in the cerebrospinal fluid of patients may simply be a marker of endothelial cell activation. CXCR4 could also play a role in promoting interactions between endothelial cells, astrocytes, and microglia. Further studies will be necessary to more completely elucidate the role of CXCL12 in the regulation of mononuclear cell trafficking across the BBB.

We also analyzed the kinetics of expression of two other secondary lymphoid chemokines, CCL19 and CCL21, during the induction of EAE via MOG immunization. Both of these chemokines are expressed by normal human brain tissue (61) and elevated in the cerebrospinal fluid of MS patients (27), and cells expressing their receptor, CCR7, accumulate within inflammatory lesions (62). Similar findings have been observed in brain tissue from mice with EAE (21). Although we also observed increased expressions of CCL19 and CCR7 mRNAs in spinal cord tissue from mice with EAE, we did not detect alterations in the expression of CCL21. As CCL19 expression has been limited to large venules (21), it is possible that this chemokine plays a role in the egress of lymphocytes out of the parenchyma during inflammation. Further studies are underway to address the role of CCL19 in lymphocyte movement through the CNS parenchyma during EAE.

Increased CXCR4 expression in the spinal cords of mice with EAE has been previously observed (63). In prior studies it was concluded that endogenous neural cells were the source of this chemokine receptor. In contrast, we observed CXCR4 expression within both mononuclear and parenchymal cells of the spinal cord in mice with EAE. Treatment with AMD3100 altered only the positions of infiltrating macrophages and T cells, leading to the loss of the typical perivascular infiltrates normally observed in EAE. Thus, although CXCR4 activity does not appear to be required for mononuclear cells to cross the endothelial barrier, it does seem to be important for the localization of these cells to the perivascular space. Because we did not see vast differences in the numbers of mononuclear cells obtained from spinal cords of PBS- vs AMD3100-treated animals, it remains unclear whether this localization is required to expose these and the microglial cells to factors produced by activated endothelial cells that would affect their proliferation. Alternatively, the enhanced expression of inflammatory cytokines observed during AMD3100 treatment may indicate that these cells are normally exposed to anti-inflammatory mediators within the perivascular space or that close interactions between T cells and macrophages at this site direct their mutual effector activities. Expressions of the anti-inflammatory cytokines IL-10 and IL-4 have been localized to perivascular macrophages within active MS lesions (64, 65). These and other factors could influence the inflammatory responses of mononuclear cells as they migrate out of the blood and into the CNS parenchyma.

Because CXCL12 is expressed by secondary lymphoid tissue, it is possible that AMD3100 exerts its effects peripherally at the lymph node. However, the administration of AMD3100 9 days postimmunization or during adoptive transfer EAE also led to increased clinical severity as compared with PBS treatment, indicating that CXCR4 antagonism during immunization is not required to observe an increased clinical severity of EAE. In addition, we observed a down-regulation of CXCL12 and CXCR4 expression in splenic tissues during the induction of EAE, suggesting that CXCL12 activity in secondary lymphoid tissues is decreased during EAE induction. This decrease in CXCL12 expression might abrogate CXCR4 activation and, therefore, any activity of AMD3100 treatment in the periphery during the immunization phase of EAE.

AMD3100 was initially developed to prevent lymphocyte entry by CXCR4 using strains of HIV-1 (66, 67). More recently, AMD3100 has been shown to induce the rapid mobilization of hemopoietic stem cell precursors, which require CXCL12/CXCR4 for their localization within the bone marrow (53, 54). In prior studies, another bone marrow stem cell mobilization agent, G-CSF, was shown to ameliorate EAE (65). This effect was associated with a shift toward anti-inflammatory and Th2 cytokines, suggesting that regulatory lymphocytes were involved. In a recent study, G-CSF was observed to down-regulate CXCL12 expression in human bone marrow, leading to the release of CD4+CD25+ regulatory T cells that were localized there via CXCL12/CXCR4 signaling (68). Although these data suggest that CNS autoimmune disease might be inhibited by the release of bone marrow-derived regulatory T cells, our results with the adoptive transfer of AMD3100-mobilized cells indicate that this mobilization alone does not regulate EAE disease expression. Although it is also possible that CXCR4 activity is required for the migration or action of regulatory T cells within the CNS, AMD3100-mobilized hemopoietic precursor cells did not affect the induction of active immunization EAE when adoptively transferred into MOGp35-55- immunized mice without AMD3100 treatment. In addition, we did not observe any differences in the spinal cord expression of regulatory T cell markers in our PBS- vs AMD3100-treated animals. Thus, CXCL12 appears to have a separate anti-inflammatory role in the CNS that does not involve the specific recruitment of regulatory T cells.

The effect of AMD3100 on autoimmune disease of the CNS is contrary to that observed in studies of autoimmunity at other tissues sites. Prior studies using murine models of arthritis and asthma have demonstrated that the disruption of CXCL12/CXCR4 signaling via the administration of AMD3100 leads to amelioration of disease (45, 69). Because the levels of CXCL12 are relatively low in uninjured murine synovium and tracheal epithelium (70, 71), high levels of its expression during inflammation within these tissues and reduced disease expression after CXCR4 inactivation are consistent with CXCL12 exerting a proinflammatory role in these autoimmune diseases. These studies also observed that CXCR4 antagonism decreased the expression of Th1 cytokines in inflamed tissues, which was not detected in our analyses of spinal cord tissues from PBS- and AMD3100-treated mice. As CXCL12 is expressed in high levels in the normal CNS, it is more logical that it would exert anti-inflammatory effects under normal circumstances. Consistent with this possibility, we found that AMD3100-treated mice had significantly increased levels of IFN-{gamma}, decreased levels of IL-10, and increased levels of cytokines and chemokines associated with monocyte and microglial activation, including TNF-{alpha} and CXCL10 (72, 73), indicating that CXCR4 activation is anti-inflammatory in the spinal cord. Others have reported that CXCR4 expression by cells of myeloid lineage is dynamic and regulated by the activation state of the cell (74, 75). The up-regulation of CXCR4 by microglial cells during activation may be important for anti-inflammatory interactions between these cells and CXCL12-expressing endothelial cells at the BBB.

An additional caveat of all pharmacological studies regards the specificity of the administered agent. The specificity of AMD3100 for CXCR4 in human leukocytes was determined to rely on interactions of the drug with two aspartic acid residues located at the interphase between the transmembrane domains and the extracellular regions of human CXCR4 (42). These aspartic acid residues are completely conserved across primate, rodent, and feline species. However, the specificity of AMD3100 for murine chemokine receptors other than CXCR4 has not been as rigorously evaluated as it has been for primate CXCR4. Thus, it is remotely possible that the in vivo use of AMD3100 could lead to nonspecific effects on alternative receptors, including those outside the chemokine receptor family. Studies using transgenic approaches could confirm the in vivo role of CXCR4 during autoimmune diseases.

In summary, CXCR4 antagonism was associated with worsening CNS autoimmune disease due to increased parenchymal penetration of mononuclear cells. The increased clinical severity of disease was associated with increased expression of inflammatory mediators and augmented microglial activation and demyelination. We propose an anti-inflammatory role for CXCL12 and CXCR4 within the CNS and suggest that inhibition of CXCR4 for the prevention of HIV-1 infection of lymphocytes should be approached with caution, as it may disrupt the normal BBB regulation of leukocyte entry and promote the migration of HIV-1-infected macrophages into the CNS.


   Acknowledgments
 
We thank Julia Sim and Judy Tollett for technical assistance. We also thank Drs. Joshua Rubin, John Russell, Anne Cross, and Michael Diamond for experimental advice and critical comments on the manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant NS04560704, National Multiple Sclerosis Society Grant RG3450, and a Washington University/Pfizer Biomedical Award (all to R.S.K). The in vivo work was performed in an animal facility supported by National Center for Research Resources Grant C06 RR012466. Back

2 E.E.M. and Q.W. contributed equally to this work. Back

3 Address correspondence and reprint requests to Dr. Robyn S. Klein, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail address: rklein{at}id.wustl.edu Back

4 Abbreviations used in this paper: BBB, blood-brain barrier; DAPI, 4',6'-diamidino-3-phenylindole; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; HPC, hemopoietic precursor cell; MOG, myelin oligodendroglial glycoprotein; MS, multiple sclerosis; QPCR, quantitative PCR. Back

Received for publication April 20, 2006. Accepted for publication September 26, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Prat, A., K. Biernacki, K. Wosik, J. P. Antel. 2001. Glial cell influence on the human blood-brain barrier. Glia 36: 45-155.
  2. Ballabh, P., A. Braun, M. Nedergaard. 2004. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16: 1-13. [Medline]
  3. Ransohoff, R. M., P. Kivisakk, G. Kidd. 2003. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3: 69-581.
  4. Frohman, E. M., M. K. Racke, C. S. Raine. 2006. Multiple sclerosis–the plaque and its pathogenesis. N. Engl. J. Med. 354: 42-955.
  5. Prat, A., J. Antel. 2005. Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18: 25-230.
  6. Huseby, E. S., D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, J. Goverman. 2001. A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J. Exp. Med. 194: 69-676.
  7. Wekerle, H.. 1993. T-cell autoimmunity in the central nervous system. Intervirology 35: 5-100. [Medline]
  8. Hauser, S. L., A. K. Bhan, F. Gilles, M. Kemp, C. Kerr, H. L. Weiner. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19: 78-587. [Medline]
  9. Alter, A., M. Duddy, S. Hebert, K. Biernacki, A. Prat, J. P. Antel, V. W. Yong, R. K. Nuttall, C. J. Pennington, D. R. Edwards, A. Bar-Or. 2003. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 170: 497-4505.
  10. Duran, I., E. M. Martinez-Caceres, J. Rio, N. Barbera, M. E. Marzo, X. Montalban. 1999. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122: 297-2307.
  11. Keszthelyi, E., S. Karlik, S. Hyduk, G. P. Rice, G. Gordon, T. Yednock, H. Horner. 1996. Evidence for a prolonged role of {alpha}4 integrin throughout active experimental allergic encephalomyelitis. Neurology 47: 053-1059.
  12. Kim, C. H.. 2004. Chemokine-chemokine receptor network in immune cell trafficking. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 43-361.
  13. Charo, I. F., R. M. Ransohoff. 2006. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354: 610-621. [Free Full Text]
  14. Kim, C. H.. 2005. The greater chemotactic network for lymphocyte trafficking: chemokines and beyond. Curr. Opin. Hematol. 12: 98-304. [Medline]
  15. Fife, B. T., G. B. Huffnagle, W. A. Kuziel, W. J. Karpus. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192: 99-905. [Abstract/Free Full Text]
  16. Huang, D. R., J. Wang, P. Kivisakk, B. J. Rollins, R. M. Ransohoff. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193: 13-726. [Medline]
  17. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192: 075-1080.
  18. Klein, R. S., L. Izikson, T. Means, H. D. Gibson, E. Lin, R. A. Sobel, H. L. Weiner, A. D. Luster. 2004. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J. Immunol. 172: 50-559.
  19. Liu, L., D. Huang, M. Matsui, T. T. He, T. Hu, J. Demartino, B. Lu, C. Gerard, R. M. Ransohoff. 2006. Severe disease, unaltered leukocyte migration, and reduced IFN-{gamma} production in CXCR3–/– mice with experimental autoimmune encephalomyelitis. J. Immunol. 176: 399-4409.
  20. McColl, S. R., S. Mahalingam, M. Staykova, L. A. Tylaska, K. E. Fisher, C. A. Strick, R. P. Gladue, K. S. Neote, D. O. Willenborg. 2004. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands. Lab. Invest. 84: 418-1429. [Medline]
  21. Alt, C., M. Laschinger, B. Engelhardt. 2002. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32: 133-2144.
  22. Banisadr, G., D. Skrzydelski, P. Kitabgi, W. Rostene, S. M. Parsadaniantz. 2003. Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18: 593-1606.
  23. Stumm, R. K., J. Rummel, V. Junker, C. Culmsee, M. Pfeiffer, J. Krieglstein, V. Hollt, S. Schulz. 2002. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J. Neurosci. 22: 5865-5878. [Abstract/Free Full Text]
  24. Jang, M. H., N. Sougawa, T. Tanaka, T. Hirata, T. Hiroi, K. Tohya, Z. Guo, E. Umemoto, Y. Ebisuno, B. G. Yang, et al 2006. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J. Immunol. 176: 803-810. [Abstract/Free Full Text]
  25. Hansson, M., A. Lundgren, K. Elgbratt, M. Quiding-Jarbrink, A. M. Svennerholm, E. L. Johansson. 2006. Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3beta) after exposure to Helicobacter pylori. Microbes Infect. 8: 841-850. [Medline]
  26. Columba-Cabezas, S., B. Serafini, E. Ambrosini, F. Aloisi. 2003. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol. 13: 38-51. [Medline]
  27. Pashenkov, M., M. Soderstrom, H. Link. 2003. Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. J. Neuroimmunol. 135: 154-160. [Medline]
  28. Krumbholz, M., D. Theil, S. Cepok, B. Hemmer, P. Kivisakk, R. M. Ransohoff, M. Hofbauer, C. Farina, T. Derfuss, C. Hartle, et al 2006. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200-211. [Abstract/Free Full Text]
  29. Klein, R. S., J. B. Rubin. 2004. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 25: 306-314. [Medline]
  30. D’Apuzzo, M., A. Rolink, M. Loetscher, J. A. Hoxie, I. Clark-Lewis, F. Melchers, M. Baggiolini, B. Moser. 1997. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur. J. Immunol. 27: 1788-1793. [Medline]
  31. Nagasawa, T., H. Kikutani, T. Kishimoto. 1994. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. USA 91: 2305-2309. [Abstract/Free Full Text]
  32. Nanki, T., P. E. Lipsky. 2000. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J. Immunol. 164: 5010-5014. [Abstract/Free Full Text]
  33. Ara, T., M. Itoi, K. Kawabata, T. Egawa, K. Tokoyoda, T. Sugiyama, N. Fujii, T. Amagai, T. Nagasawa. 2003. A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo. J. Immunol. 170: 4649-4655. [Abstract/Free Full Text]
  34. Onai, N., Y. Zhang, H. Yoneyama, T. Kitamura, S. Ishikawa, K. Matsushima. 2000. Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. Blood 96: 2074-2080. [Abstract/Free Full Text]
  35. Lu, M., E. A. Grove, R. J. Miller. 2002. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc. Natl. Acad. Sci. USA 99: 7090-7095. [Abstract/Free Full Text]
  36. Pujol, F., P. Kitabgi, H. Boudin. 2005. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J. Cell Sci. 118: 1071-1080. [Abstract/Free Full Text]
  37. Stumm, R. K., C. Zhou, T. Ara, F. Lazarini, M. Dubois-Dalcq, T. Nagasawa, V. Hollt, S. Schulz. 2003. CXCR4 regulates interneuron migration in the developing neocortex. J. Neurosci. 23: 5123-5130. [Abstract/Free Full Text]
  38. Zou, Y. R., A. H. Kottmann, M. Kuroda, I. Taniuchi, D. R. Littman. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595-599. [Medline]
  39. Garcia-Vicuna, R., M. V. Gomez-Gaviro, M. J. Dominguez-Luis, M. K. Pec, I. Gonzalez-Alvaro, J. M. Alvaro-Gracia, F. Diaz-Gonzalez. 2004. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 50: 3866-3877. [Medline]
  40. Nanki, T., K. Hayashida, H. S. El-Gabalawy, S. Suson, K. Shi, H. J. Girschick, S. Yavuz, P. E. Lipsky. 2000. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 165: 6590-6598. [Abstract/Free Full Text]
  41. Nagase, H., K. Kudo, S. Izumi, K. Ohta, N. Kobayashi, M. Yamaguchi, K. Matsushima, Y. Morita, K. Yamamoto, K. Hirai. 2001. Chemokine receptor expression profile of eosinophils at inflamed tissue sites: decreased CCR3 and increased CXCR4 expression by lung eosinophils. J. Allergy Clin. Immunol. 108: 563-569. [Medline]
  42. Hatse, S., K. Princen, G. Bridger, E. De Clercq, D. Schols. 2002. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527: 255-262. [Medline]
  43. De Clercq, E.. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2: 581-587. [Medline]
  44. Ma, Q., D. Jones, P. R. Borghesani, R. A. Segal, T. Nagasawa, T. Kishimoto, R. T. Bronson, T. A. Springer. 1998. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA 95: 9448-9453. [Abstract/Free Full Text]
  45. Matthys, P., S. Hatse, K. Vermeire, A. Wuyts, G. Bridger, G. W. Henson, E. De Clercq, A. Billiau, D. Schols. 2001. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-{gamma} receptor-deficient mice. J. Immunol. 167: 4686-4692. [Abstract/Free Full Text]
  46. Lukacs, N. W., A. Berlin, D. Schols, R. T. Skerlj, G. J. Bridger. 2002. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol. 160: 1353-1360. [Abstract/Free Full Text]
  47. Gimenez, M. A., J. Sim, A. S. Archambault, R. S. Klein, J. H. Russell. 2006. A tumor necrosis factor receptor 1-dependent conversation between central nervous system-specific T cells and the central nervous system is required for inflammatory infiltration of the spinal cord. Am. J. Pathol. 168: 1200-1209. [Abstract/Free Full Text]
  48. Klein, R. S., E. Lin, B. Zhang, A. D. Luster, J. Tollett, M. A. Samuel, M. Engle, M. S. Diamond. 2005. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79: 11457-11466. [Abstract/Free Full Text]
  49. Leers, M. P., B. Schutte, P. H. Theunissen, F. C. Ramaekers, M. Nap. 1999. Heat pretreatment increases resolution in DNA flow cytometry of paraffin-embedded tumor tissue. Cytometry 35: 260-266. [Medline]
  50. Williams, K. C., R. W. Zhao, K. Ueno, W. F. Hickey. 1996. PECAM-1 (CD31) expression in the central nervous system and its role in experimental allergic encephalomyelitis in the rat. J. Neurosci. Res. 45: 747-757. [Medline]
  51. Rubin, J. B., A. L. Kung, R. S. Klein, J. A. Chan, Y. Sun, K. Schmidt, M. W. Kieran, A. D. Luster, R. A. Segal. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA 100: 13513-13518. [Abstract/Free Full Text]
  52. Narumi, S., T. Kaburaki, H. Yoneyama, H. Iwamura, Y. Kobayashi, K. Matsushima. 2002. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32: 1784-1791. [Medline]
  53. Larochelle, A., A. Krouse, M. Metzger, D. Orlic, R. E. Donahue, S. Fricker, G. Bridger, C. E. Dunbar, P. Hematti. 2006. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in non-human primates. Blood 107: 3772-3778. [Abstract/Free Full Text]
  54. Liles, W. C., H. E. Broxmeyer, E. Rodger, B. Wood, K. Hubel, S. Cooper, G. Hangoc, G. J. Bridger, G. W. Henson, G. Calandra, D. C. Dale. 2003. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728-2730. [Abstract/Free Full Text]
  55. Broxmeyer, H. E., C. M. Orschell, D. W. Clapp, G. Hangoc, S. Cooper, P. A. Plett, W. C. Liles, X. Li, B. Graham-Evans, T. B. Campbell, et al 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201: 1307-1318. [Abstract/Free Full Text]
  56. Fontenot, J. D., M. A. Gavin, A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. [Medline]
  57. Sorensen, T. L., C. Trebst, P. Kivisakk, K. L. Klaege, A. Majmudar, R. Ravid, H. Lassmann, D. B. Olsen, R. M. Strieter, R. M. Ransohoff, F. Sellebjerg. 2002. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127: 59-68. [Medline]
  58. Glabinski, A. R., M. Krakowski, Y. Han, T. Owens, R. M. Ransohoff. 1999. Chemokine expression in GKO mice (lacking interferon-{gamma}) with experimental autoimmune encephalomyelitis. J. Neurovirol. 5: 95-101. [Medline]
  59. Rock, R. B., S. Hu, A. Deshpande, S. Munir, B. J. May, C. A. Baker, P. K. Peterson, V. Kapur. 2005. Transcriptional response of human microglial cells to interferon-{gamma}. Genes Immun. 6: 712-719. [Medline]
  60. Heppner, F. L., M. Greter, D. Marino, J. Falsig, G. Raivich, N. Hovelmeyer, A. Waisman, T. Rulicke, M. Prinz, J. Priller, et al 2005. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11: 146-152. [Medline]
  61. Smith, J. R., R. M. Braziel, S. Paoletti, M. Lipp, M. Uguccioni, J. T. Rosenbaum. 2003. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101: 815-821.
  62. Serafini, B., B. Rosicarelli, R. Magliozzi, E. Stigliano, F. Aloisi. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14: 164-174. [Medline]
  63. Glabinski, A. R., S. O’Bryant, K. Selmaj, R. M. Ransohoff. 2000. CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 917: 135-144. [Medline]
  64. Hulshof, S., L. Montagne, C. J. De Groot, P. Van Der Valk. 2002. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 38: 24-35. [Medline]
  65. Zavala, F., S. Abad, S. Ezine, V. Taupin, A. Masson, J. F. Bach. 2002. G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J. Immunol. 168: 2011-2019. [Abstract/Free Full Text]
  66. De Clercq, E.. 2005. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev. Med. Chem. 5: 805-824. [Medline]
  67. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, et al 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquired Immune Defic. Syndr. 37: 1253-1262.
  68. Zou, L., B. Barnett, H. Safah, V. F. Larussa, M. Evdemon-Hogan, P. Mottram, S. Wei, O. David, T. J. Curiel, W. Zou. 2004. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64: 8451-8455. [Abstract/Free Full Text]
  69. Gonzalo, J. A., C. M. Lloyd, A. Peled, T. Delaney, A. J. Coyle, J. C. Gutierrez-Ramos. 2000. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 {alpha} in the inflammatory component of allergic airway disease. J. Immunol. 165: 499-508. [Abstract/Free Full Text]
  70. Pablos, J. L., B. Santiago, M. Galindo, C. Torres, M. T. Brehmer, F. J. Blanco, F. J. Garcia-Lazaro. 2003. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J. Immunol. 170: 2147-2152. [Abstract/Free Full Text]
  71. Gomperts, B. N., J. A. Belperio, P. N. Rao, S. H. Randell, M. C. Fishbein, M. D. Burdick, R. M. Strieter. 2006. Circulating progenitor epithelial cells traffic via CXCR4/CXCL12 in response to airway injury. J. Immunol. 176: 1916-1927. [Abstract/Free Full Text]
  72. Trinidad, A. G., M. Luisa de la Puerta, N. Fernandez, Y. Bayon, M. S. Crespo, A. Alonso. 2006. Coupling of C3bi to IgG inhibits the tyrosine phosphorylation signaling cascade downstream Syk and reduces cytokine induction in monocytes. J. Leukocyte Biol. 79: 1073-1082. [Abstract/Free Full Text]
  73. Hinkerohe, D., D. Smikalla, A. Haghikia, K. Heupel, C. G. Haase, R. Dermietzel, P. M. Faustmann. 2005. Effects of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture model. Glia 52: 85-97. [Medline]
  74. Dorsch, M., Y. Qiu, D. Soler, N. Frank, T. Duong, A. Goodearl, S. O’Neil, J. Lora, C. C. Fraser. 2005. PK1/EG-VEGF induces monocyte differentiation and activation. J. Leukocyte Biol. 78: 426-434. [Abstract/Free Full Text]
  75. Flynn, G., S. Maru, J. Loughlin, I. A. Romero, D. Male. 2003. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol. 136: 84-93. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. E. McCandless, M. Budde, J. R. Lees, D. Dorsey, E. Lyng, and R. S. Klein
IL-1R Signaling within the Central Nervous System Regulates CXCL12 Expression at the Blood-Brain Barrier and Disease Severity during Experimental Autoimmune Encephalomyelitis
J. Immunol., July 1, 2009; 183(1): 613 - 620.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Meiron, Y. Zohar, R. Anunu, G. Wildbaum, and N. Karin
CXCL12 (SDF-1{alpha}) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells
J. Exp. Med., October 27, 2008; 205(11): 2643 - 2655.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. E. McCandless, B. Zhang, M. S. Diamond, and R. S. Klein
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis
PNAS, August 12, 2008; 105(32): 11270 - 11275.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. E. McCandless, L. Piccio, B. M. Woerner, R. E. Schmidt, J. B. Rubin, A. H. Cross, and R. S. Klein
Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis
Am. J. Pathol., March 1, 2008; 172(3): 799 - 808.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. Sitati, E. E. McCandless, R. S. Klein, and M. S. Diamond
CD40-CD40 Ligand Interactions Promote Trafficking of CD8+ T Cells into the Brain and Protection against West Nile Virus Encephalitis
J. Virol., September 15, 2007; 81(18): 9801 - 9811.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
R. Stumm and V. Hollt
CXC chemokine receptor 4 regulates neuronal migration and axonal pathfinding in the developing nervous system: implications for neuronal regeneration in the adult brain
J. Mol. Endocrinol., March 1, 2007; 38(3): 377 - 382.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCandless, E. E.
Right arrow Articles by Klein, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCandless, E. E.
Right arrow Articles by Klein, R. S.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS